Trials / Completed
CompletedNCT06783192
A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
A Study to Assess the Effects of Single Oral Doses of MK-8527 on the Single-Dose Pharmacokinetics of an Oral Contraceptive (Levonorgestrel and Ethinyl Estradiol) in Healthy Adult Postmenopausal or Oophorectomized Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to assess the effect of a single dose of MK-8527 on the single-dose pharmacokinetics (PK) and the safety and tolerability of levonorgestrel/ethinyl estradiol (LNG/EE) in healthy adult postmenopausal or ovariectomized female participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8527 | MK-8527 capsule taken by mouth |
| DRUG | LNG/EE | LNG/EE combination tablet taken by mouth. |
Timeline
- Start date
- 2023-08-14
- Primary completion
- 2023-10-11
- Completion
- 2023-10-11
- First posted
- 2025-01-20
- Last updated
- 2025-01-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06783192. Inclusion in this directory is not an endorsement.